» Articles » PMID: 34829753

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC

Overview
Journal Biomedicines
Date 2021 Nov 27
PMID 34829753
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading contributor to the global burden of chronic liver diseases. The phenotypic umbrella of NAFLD spans from simple and reversible steatosis to nonalcoholic steatohepatitis (NASH), which may worsen into cirrhosis and hepatocellular carcinoma (HCC). Notwithstanding, HCC may develop also in the absence of advanced fibrosis, causing a delayed time in diagnosis as a consequence of the lack of HCC screening in these patients. The precise event cascade that may precipitate NASH into HCC is intricate and it entails diverse triggers, encompassing exaggerated immune response, endoplasmic reticulum (ER) and oxidative stress, organelle derangement and DNA aberrancies. All these events may be accelerated by both genetic and environmental factors. On one side, common and rare inherited variations that affect hepatic lipid remodeling, immune microenvironment and cell survival may boost the switching from steatohepatitis to liver cancer, on the other, diet-induced dysbiosis as well as nutritional and behavioral habits may furtherly precipitate tumor onset. Therefore, dietary and lifestyle interventions aimed to restore patients' health contribute to counteract NASH progression towards HCC. Even more, the combination of therapeutic strategies with dietary advice may maximize benefits, with the pursuit to improve liver function and prolong survival.

Citing Articles

DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application.

Longo M, Paolini E, Di Benedetto P, Tomassini E, Meroni M, Dongiovanni P Int J Mol Sci. 2024; 25(16).

PMID: 39201759 PMC: 11354429. DOI: 10.3390/ijms25169074.


Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.

Li A, Wang R, Zhao Y, Zhao P, Yang J Metabolites. 2024; 14(6).

PMID: 38921460 PMC: 11205353. DOI: 10.3390/metabo14060325.


A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.

Ma Y, Wang J, Xiao W, Fan X Front Med (Lausanne). 2024; 11:1410668.

PMID: 38895182 PMC: 11184143. DOI: 10.3389/fmed.2024.1410668.


Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.

Meroni M, Longo M, Dongiovanni P Front Endocrinol (Lausanne). 2024; 15:1411706.

PMID: 38846491 PMC: 11153718. DOI: 10.3389/fendo.2024.1411706.


Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis.

Gao B, Chen Z, Shi M, Mo Y, Xiao H, Xie Y Front Pharmacol. 2023; 14:1240649.

PMID: 37771721 PMC: 10523561. DOI: 10.3389/fphar.2023.1240649.


References
1.
Yoshimoto S, Loo T, Atarashi K, Kanda H, Sato S, Oyadomari S . Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013; 499(7456):97-101. DOI: 10.1038/nature12347. View

2.
Bruschi F, Tardelli M, Einwallner E, Claudel T, Trauner M . PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. Int J Mol Sci. 2020; 21(22). PMC: 7698885. DOI: 10.3390/ijms21228711. View

3.
Zang B, Chen C, Zhao J . PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population. Aging (Albany NY). 2020; 12(4):3771-3790. PMC: 7066885. DOI: 10.18632/aging.102845. View

4.
Eldafashi N, Darlay R, Shukla R, McCain M, Watson R, Liu Y . A Role in the Genetic Predisposition to NAFLD-HCC?. Cancers (Basel). 2021; 13(6). PMC: 8003582. DOI: 10.3390/cancers13061412. View

5.
Sun T, Xie H, Li Z, Kong L, Gou X, Li D . miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma. Am J Transl Res. 2017; 9(1):103-114. PMC: 5250707. View